Table 2.
Events, Person-Years of Follow-up and Events/Person-Years by Medication Use for Each Outcome
| Outcome | Physical Activity | Successful Aging Health Education | ||||
|---|---|---|---|---|---|---|
| Events/N | PY | Events/100 PY | Events/N | PY | Events/100 PY | |
| MMD* | ||||||
| ACE inhibitor use | 86/260 | 556.65 | 15.45 | 105/255 | 522.55 | 20.09 |
| Other antihypertensive use | 120/401 | 904.22 | 13.27 | 149/409 | 887.02 | 16.80 |
| No antihypertensive use | 40/156 | 360.74 | 11.09 | 36/152 | 362.90 | 9.92 |
| Persistent MMD† | ||||||
| ACE inhibitor use | 41/260 | 575.35 | 7.13 | 68/255 | 541.39 | 12.56 |
| Other antihypertensive use | 62/401 | 930.20 | 6.67 | 79/409 | 920.16 | 8.59 |
| No antihypertensive use | 17/156 | 366.15 | 4.64 | 15/152 | 370.74 | 4.05 |
Notes: ACE = angiotensin-converting enzyme; MMD = major mobility disability; PY = person-years.
*Defined by the inability to complete a 400-m walk test within 15min without sitting and without the help of another person or walker.
†Defined by two consecutive MMD assessments separated by 6 months or MMD followed by death. 100 PY = 100 person-years.